Propensity Scores, IPTW, and Matching Methods for Confounding Control In the field of Real-World Evidence (RWE) submissions to the FDA, the correct application of statistical methods is critical for generating reliable results that support regulatory decisions. This article provides a detailed step-by-step guide on using propensity scores, inverse probability of treatment weighting (IPTW), and matching methods as effective strategies for confounding control in your RWE study design methodology. Understanding the Basics of Confounding in RWE Studies Confounding occurs when an external variable influences both the treatment and outcome, leading to biased estimates of treatment effects. For RWE studies, which often…

Emulating Target Trials using RWD for FDA Facing RWE Analyses Introduction to RWE Study Design Methodology As regulatory agencies, including the FDA, increasingly embrace Real-World Evidence (RWE) for supporting regulatory decision-making, understanding the nuances of RWE study design methodology becomes essential for professionals in the pharmaceutical and medtech industries. RWE is derived from data obtained outside the traditional randomized controlled trials (RCTs) and can provide significant insights into patient outcomes, treatment effectiveness, and safety. This comprehensive tutorial on RWE study design methodology for FDA submissions will delve deeply into the concept of target trial emulation, utilizing propensity scores, external control…

Cohort, Case Control, and Hybrid Designs in Regulatory Grade RWE Real-World Evidence (RWE) has gained prominence in the landscape of regulatory submissions, particularly with the FDA’s increasing interest in leveraging data derived from diverse healthcare environments. This comprehensive guide aims to equip regulatory, biostatistics, health economics and outcomes research (HEOR), and data standards professionals in pharma and medtech with a nuanced understanding of cohort, case-control, and hybrid designs for RWE studies. Adhering to the stringent requirements set by the FDA while designing these studies is essential to ensure they meet the standard of regulatory-grade RWE. Understanding RWE and Its Regulatory…

How to select appropriate comparators in RWE studies for regulators Introduction to Real-World Evidence (RWE) and Comparator Selection In recent years, the utilization of Real-World Evidence (RWE) in regulatory submissions has gained significant traction. RWE refers to the clinical evidence derived from sources outside of traditional randomized controlled trials (RCTs). This evidence is critical in enhancing the understanding of treatment effectiveness in the actual population. However, for RWE to be robust and provide valuable insights for regulatory review, the selection of appropriate comparators is essential. This article outlines a step-by-step tutorial on how to select comparators in RWE studies for…

Study Design Choices for Real World Evidence Submissions to FDA Real-world evidence (RWE) is increasingly important in the regulatory landscape for pharmaceuticals and medical devices. The FDA actively encourages sponsors to submit quality RWE as part of the New Drug Application (NDA), Biologics License Application (BLA), and other regulatory submissions. This article offers a tutorial on RWE study design methodology for FDA submissions, equipping professionals in regulatory affairs, biostatistics, health economics and outcomes research (HEOR), and data standards with essential insights. We cover the identification of appropriate study designs, methods to control confounding, the use of external control arms, and…

Case studies of RWE designs accepted by FDA for decision making Case Studies of RWE Designs Accepted by FDA for Decision Making Real-World Evidence (RWE) is increasingly recognized by the FDA and other regulatory bodies as a fundamental part of the drug development and approval process. This article aims to provide a comprehensive guide to RWE study design methodology for FDA submissions, illustrating with case studies that highlight successful approaches. It will focus on key concepts such as target trial emulation, propensity scores, external control arms, and confounding control. Moreover, it emphasizes the importance of developing regulatory-grade RWE that meets…

Designing External Control Arm Studies Using RWD for Rare Diseases As the landscape of clinical research evolves, the use of Real-World Data (RWD) has become increasingly significant, particularly for rare diseases where traditional clinical trial methods may fall short. This article provides a comprehensive guide on RWE study design methodology for FDA submissions, focusing specifically on external control arm studies. Our objective is to offer regulatory, biostatistics, HEOR, RWE, and data standards professionals a step-by-step framework for implementing robust study designs that fulfill FDA expectations. Understanding External Control Arm Studies External control arm studies represent an innovative approach in clinical…

Sensitivity analyses and negative controls to build confidence in RWE Sensitivity analyses and negative controls to build confidence in RWE In the evolving landscape of healthcare research, regulatory authorities, including the FDA, are increasingly focusing on Real-World Evidence (RWE) as a substantial component for submissions related to drug and device approval processes. RWE encompasses real-world data (RWD) collected outside the confines of traditional clinical trials, and its application is poised to redefine evidence generation strategies across the biopharmaceutical domain. However, the credibility of RWE hinges critically on robust study design methodologies that can effectively address potential biases and confounding variables….

Sample Size and Power Considerations for RWE Supporting Label Changes In the evolving landscape of regulatory science, the use of Real-World Evidence (RWE) is pivotal in informing label changes for pharmaceuticals and medical devices. The U.S. Food and Drug Administration (FDA) has increasingly acknowledged RWE’s potential in demonstrating safety and effectiveness through evidence gathered outside of the traditional randomized controlled trial (RCT) framework. This article outlines the critical sample size and power considerations that should be taken into account during the RWE study design methodology for FDA submissions. Understanding the Importance of Sample Size in RWE Studies The sample size…

Handling Immortal Time Bias and Other Design Pitfalls in RWE Studies Real-World Evidence (RWE) has taken a pivotal role in the landscape of regulatory science, particularly with the increasing focus on RWE study design methodology FDA submissions. The U.S. Food and Drug Administration (FDA) has recognized that RWE can provide valuable insights regarding the use, benefits, and risks of medical products. However, RWE studies must be crafted with meticulous consideration to avoid design pitfalls, such as immortal time bias and other confounding factors. This guide is meant to serve as an essential resource for regulatory, biostatistics, Health Economics and Outcomes…